Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Molecules Année : 2021

Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

Oumaima Zidi
Nessrine Souai
Henda Raies
  • Fonction : Auteur
Farhat Ben Ayed
  • Fonction : Auteur
Amel Mezlini
  • Fonction : Auteur
Sonia Mezrioui
  • Fonction : Auteur
Fabrice Tranchida
Jean-Marc Sabatier
Amor Mosbah
Ameur Cherif
Laetitia Shintu
Soumaya Kouidhi
  • Fonction : Auteur

Résumé

Breast cancer (BC) is the most common form of cancer among women worldwide. Despite the huge advancements in its treatment, the exact etiology of breast cancer still remains unresolved. There is an increasing interest in the role of the gut microbiome in modulating the anti-cancer therapeutic response. It seems that alteration of the microbiome-derived metabolome potentially promotes carcinogenesis. Taken together, metabolomics has arisen as a fascinating new omics field to screen promising metabolic biomarkers. In this study, fecal metabolite profiling was performed using NMR spectroscopy, to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy (NAC) for breast cancer. Metabolic profiles of feces from patients (n = 8) following chemotherapy treatment cycles were studied. Interestingly, amino acids were found to be upregulated, while lactate and fumaric acid were downregulated in patients under the second and third cycles compared with patients before treatment. Furthermore, short-chain fatty acids (SCFAs) were significantly differentiated between the studied groups. These results strongly suggest that chemotherapy treatment plays a key role in modulating the fecal metabolomic profile of BC patients. In conclusion, we demonstrate the feasibility of identifying specific fecal metabolic profiles reflecting biochemical changes that occur during the chemotherapy treatment. These data give an interesting insight that may complement and improve clinical tools for BC monitoring.
Fichier principal
Vignette du fichier
molecules-26-02266.pdf (2.27 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-03358035 , version 1 (10-07-2023)

Licence

Paternité

Identifiants

Citer

Oumaima Zidi, Nessrine Souai, Henda Raies, Farhat Ben Ayed, Amel Mezlini, et al.. Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers. Molecules, 2021, 26 (8), pp.2266. ⟨10.3390/molecules26082266⟩. ⟨hal-03358035⟩
30 Consultations
19 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More